<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746483</url>
  </required_header>
  <id_info>
    <org_study_id>AZ-CF2001</org_study_id>
    <nct_id>NCT03746483</nct_id>
  </id_info>
  <brief_title>OPTION: A Trial to Assess the Safety &amp; Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis</brief_title>
  <acronym>OPTION</acronym>
  <official_title>A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AzurRx BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AzurRx BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs
      porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic
      insufficiency (EPI) due to cystic fibrosis (CF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, multi-center, 2x2 crossover study assessing the safety and
      efficacy of MS1819-SD vs porcine PERT given at the same dose that was being administered
      during the pre-study period.

      MS1819-SD will be assessed in a 2x2 crossover including at least 30 patients completing both
      periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Actual">July 27, 2019</completion_date>
  <primary_completion_date type="Actual">July 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2x2 Crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Unblinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of MS1819-SD by number of subjects reporting 1 or more adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of subjects reporting 1 or more adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of MS1819-SD: Coefficient of fat absorption (CFA)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Coefficient of fat absorption (CFA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool weights</measure>
    <time_frame>6 weeks</time_frame>
    <description>The relative efficacy of MS1819-SD compared to porcine PERT will be assessed using stool weights</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs and symptoms of malabsorption</measure>
    <time_frame>6 weeks</time_frame>
    <description>The relative efficacy of MS1819 compared to porcine PERT will be assessed using signs and symptoms of malabsorption</description>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Exocrine Pancreatic Insufficiency (EPI)</condition>
  <condition>Cystic Fibrosis (CF)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MS1819-SD</intervention_name>
    <description>MS1819-SD, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Porcine PERT</intervention_name>
    <description>Porcine PERT is being used as a comparator to MS1819-SD as a second drug/intervention</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cystic fibrosis, based on 2 clinical features consistent with CF, plus initial
             diagnostic sweat chloride ≥ 60 mmol/L

          2. Under stable dose of porcine PERT

          3. A fair or better nutritional status

          4. Fecal elastase &lt;100 µg/g

          5. Standard-of-care medications including CFTR modulators are allowed

        Exclusion Criteria:

          1. History or diagnosis of fibrosing colonopathy

          2. Any chronic diarrheal illness unrelated to pancreatic insufficiency

          3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥5 ×upper
             limit of normal (ULN), or total bilirubin level ≥1.5 ×ULN at the Screening visit

          4. Feeding via an enteral tube during 6 months before screening

          5. Forced expiratory volume ≤30% at the Screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site 105</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 102</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 107</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 101</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 111</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 108</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 103</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 110</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 104</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 106</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 109</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 203</name>
      <address>
        <city>Karpacz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 202</name>
      <address>
        <city>Rabka-Zdrój</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 204</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exocrine pancreatic insufficiency</keyword>
  <keyword>EPI</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>CF</keyword>
  <keyword>Pancreatic enzyme replacement therapy</keyword>
  <keyword>Lipase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

